lenalidomide has been researched along with Asymptomatic Multiple Myeloma in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 14 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bhutani, M; Braylan, R; Calvo, KR; Choyke, P; Dew, A; Dulau-Florea, A; Emanuel, M; Figg, WD; Hill, E; Kazandjian, D; Korde, N; Kwok, M; Landgren, O; Lee, MJ; Lee, S; Lindenberg, L; Mailankody, S; Manasanch, E; Maric, I; Mena, E; Morrison, C; Patel, N; Petrosyan, A; Roschewski, M; Roswarski, J; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Trepel, JB; Turkbey, B; Wang, HW; Wang, W; Yuan, C; Zhang, Y | 1 |
| Kunacheewa, C; Manasanch, EE | 2 |
| Akinyemi, O; Ali, A; Araoye, MO; Asemota, J; Ojo, AS; Ojukwu, SG; Saleh, M; Sarma, R | 1 |
| Kumar, S; Lonial, S; Mateos, MV; Rajkumar, SV | 1 |
| Arguiñano, JM; Bargay, J; Bladé, J; de Arriba, F; Hernández, MT; Lahuerta, JJ; López, J; López-Corral, L; Mateos, MV; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Rosiñol, L; Rubia, J; Salvador, C; San-Miguel, J | 1 |
| Lesokhin, AM; Maclachlan, KH | 1 |
| Aguet, F; Anand, S; Aranha, MP; Badros, AZ; Baginska, J; Bhutani, M; Boruchov, A; Bustoros, M; Dutta, AK; Flechon, L; Getz, G; Ghobrial, IM; Hallisey, M; Haradhvala, NJ; Heilpern-Mallory, D; Jakubowiak, A; Laubach, J; Lightbody, ED; Manier, S; Mateos, MV; Matous, J; Mouhieddine, TH; Nadeem, O; Redd, RA; Richardson, P; Rosenblatt, JM; Savell, A; Sklavenitis-Pistofidis, R; Su, NK; Tahri, S; Trippa, L; Ujwary, S; Usmani, SZ; Varmeh, S; Vredenburgh, JJ; Wu, T; Yee, AJ; Zavidij, O; Zonder, J | 1 |
| Agathokleous, A; Georgiou, S; Kyriakou, G; Marnellos, P; Solomou, EE; Symeonidis, A | 1 |
| Anderson, DM; Buadi, FK; Dhodapkar, MV; Emmons, RV; Fonseca, R; Jacobus, S; Kaufman, JL; Kumar, S; Lonial, S; Mahindra, A; Matous, JV; O'Brien, T; Orlowski, RZ; Rajkumar, SV; Wagner, LI; Weiss, M; Yacoub, AM | 1 |
| Raje, N; Yee, AJ | 1 |
| Dhodapkar, MV; Lonial, S; Rajkumar, SV | 1 |
| Biran, N; Donato, ML; Goldberg, S; Ip, A; Kaur, G; Siegel, DS; Vesole, DH | 1 |
| Joseph, NS; Lonial, S | 1 |
| Goodman, AM; Kim, MS; Prasad, V | 1 |
| Bae, J; Kaufman, JL; Nooka, AK; Peterkin, D; Raje, NS; Richardson, PG; Wang, ML; Yee, AJ | 1 |
5 review(s) available for lenalidomide and Asymptomatic Multiple Myeloma
| Article | Year |
|---|---|
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
Topics: Disease Progression; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Quality of Life; Smoldering Multiple Myeloma | 2021 |
The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.
Topics: Disease Progression; Humans; Lenalidomide; Randomized Controlled Trials as Topic; Smoldering Multiple Myeloma; Watchful Waiting | 2022 |
Smoldering multiple myeloma current treatment algorithms.
Topics: Algorithms; Biological Products; Disease Progression; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Paraproteinemias; Smoldering Multiple Myeloma | 2022 |
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Disease Progression; Drug Administration Schedule; Early Detection of Cancer; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Randomized Controlled Trials as Topic; Smoldering Multiple Myeloma; Survival Analysis | 2020 |
Practical approach to the management of smoldering myeloma.
Topics: Aged; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Randomized Controlled Trials as Topic; Smoldering Multiple Myeloma | 2020 |
4 trial(s) available for lenalidomide and Asymptomatic Multiple Myeloma
| Article | Year |
|---|---|
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Smoldering Multiple Myeloma | 2021 |
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Smoldering Multiple Myeloma | 2022 |
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Male; Middle Aged; Quality of Life; Smoldering Multiple Myeloma | 2020 |
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Immunogenicity, Vaccine; Immunotherapy; Lenalidomide; Male; Middle Aged; Smoldering Multiple Myeloma; Treatment Outcome | 2018 |
7 other study(ies) available for lenalidomide and Asymptomatic Multiple Myeloma
| Article | Year |
|---|---|
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Smoldering Multiple Myeloma; Tumor Microenvironment | 2022 |
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Topics: Biomarkers; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Multiple Myeloma; Smoldering Multiple Myeloma | 2022 |
Reversal of skin changes in smoldering myeloma with clinical presentation of POEMS syndrome with a lenalidomide-based regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dyspnea; Edema; Humans; Lenalidomide; Male; Muscle Weakness; Nails, Malformed; POEMS Syndrome; Skin; Smoldering Multiple Myeloma | 2019 |
How We Approach Smoldering Multiple Myeloma.
Topics: Humans; Lenalidomide; Smoldering Multiple Myeloma | 2020 |
Reply to N. Biran et al.
Topics: Humans; Lenalidomide; Smoldering Multiple Myeloma | 2020 |
Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
Topics: Biological Products; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Smoldering Multiple Myeloma | 2020 |
Persistent challenges with treating multiple myeloma early.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Cost of Illness; Dexamethasone; Disease Progression; Early Detection of Cancer; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Protease Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Smoldering Multiple Myeloma; Time-to-Treatment | 2021 |